BHMP
INDV icon

Bardin Hill Management Partners’s Indivior Pharmaceuticals INDV Stock Holding History

Bardin Hill Management Partners’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-87,611
Closed -$2.11M – 3
2025
Q3 		$2.11M Buy
+87,611
New +$1.83M 2.63% 5

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bardin Hill Management Partners's INDV Position: Q4 2025 in Review

Bardin Hill Management Partners sold out of Indivior Pharmaceuticals (INDV) in Q4 2025, closing a stake of 87,611 shares — an estimated $2.11M sold.

Bardin Hill Management Partners first reported a position in INDV in Q3 2025 and held it in 1 quarter. The position peaked at $2.11M in Q3 2025. 259 funds tracked by Wall St. Rank hold INDV as of Q4 2025.

  • Bardin Hill Management Partners reported no remaining Indivior Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Bardin Hill Management Partners sold 87,611 Indivior Pharmaceuticals shares in Q4 2025, an estimated $2.11M.
  • Bardin Hill Management Partners first reported a position in Indivior Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Bardin Hill Management Partners's Indivior Pharmaceuticals position peaked at $2.11M in Q3 2025.
  • 259 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q4 2025.

Based on Bardin Hill Management Partners's 13F filing for Q4 2025.